At Week 25, mean changes from baseline in PtGA, pain, HAQ–DI, and PCS scores were statistically significant and exceeded minimum clinically important differences (MCID) in the biweekly treatment group, compared with little to no improvement in placebo group.

Statistically significant improvements greater than or equal to MCID were reported in 6 of 8 SF–36 domains.